MiNA Therapeutics Gains Another Partner in Lilly for its saRNA Technology
By Michelle Liu
Pharma Deals Review: Vol 2021 Issue 6 (Table of Contents)
Published: 17 Jun-2021
DOI: 10.3833/pdr.v2021.i6.2612 ISSN: 1756-7874
Section: Research & Development
Fulltext:
Abstract
Expanding its RNA therapeutics portfolio, Eli Lilly has entered into a collaboration agreement with MiNA Therapeutics to develop small activating RNA (saRNA) candidates for up to five targets...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS